- Short Communication
- Open access
- Published:
H. pylori-induced higher C-reactive protein in obese African Americans
Artery Research volume 3, pages 39–42 (2009)
Summary
African Americans are more susceptible to develop insulin resistance, obesity, Type 2 diabetes, and coronary heart disease (CHD), and systemic inflammation is central to the pathophysiology of these chronic diseases. African Americans are also more likely to contract H. pylori (cagA) infections during their childhood. However, the contribution of H. pylori infection to the degree of overall systemic inflammation in these chronic diseases is not known. Therefore, we studied 46 apparently healthy African Americans, over 40 years of age who were infected with H. pylori (cagA). These volunteers were assessed at baseline and after treatment with triple regimen drug therapy to eradicate H. pylori. All but 3 subjects were found to be free of this infection by urea breath test (UBT) after the treatment period. No hyperhomocysteinemia was found in these subjects and there were no significant changes in the level of homocysteine (tHcy), folate and B12; however, CRP levels measured by high sensitivity assay showed a significant (p = 0.02) decrease 2 months after the eradication. We further stratified CRP values according to the BMI <27 and >27. There was more profound reduction in CRP in the more obese group (i.e., BMI >27) from 54.26 ± 23.67 to 18.73 ± 17.39 mg/l (p = 0.01), compared with the leaner subjects in whom CRP decreases from 8.88 ± 6.23 to 4.94 ± 6.21 mg/L (p = 0.04), after eradication of the H. pylori (cagA) infection. The level of CRP, however, remained significantly higher in the obese subjects even after the eradication of this infection, indicative of a smaller residual influence of adiposity on CRP. Thus, a major component of systemic inflammation in African Americans may be attributable to chronic H. pylori infection.
References
Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999;340:115–26.
Libby P, Egan D, Skarlatos S. Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research. Circulation 1997;96:4095–103.
Hocker M, Hohenberger P. Helicobacter pylori virulence factors-one part of a big picture. Lancet 2003;362:1231–3.
Graham DY, Adam E, Reddy GT, Agarwal JP, Agarwal R, Evans Jr DJ, et al. Seroepidemiology of H. pylori infection in India: comparison of developing and developed countries. Dig Dis Sci 1991;36:1084–8.
Singh RK, McMohan AD, Patel H, Packard CJ, Rathbone BJ, Samani NJ. Prospective analysis of the association of infection with cagA bearing strains of Helicobacter pylori and coronary heart disease. Heart 2002;88:43–6.
Pasceri V, Cammarota G, Patti G, Cuoco L, Gasbarrini A, Grillo RL, et al. Association of virulent Helicobacter pylori strains with ischemic heart disease. Circulation 1998;97:1675–9.
Farmer JA, Torre-Amione G. Atherosclerosis and inflammation. Curr Atheroscler Rep 2002;4:92–8.
Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997;277:1775–81.
Khaled MA, Cornwell PE. Hyperhomocysteinemia due to H. pylori. Atherosclerosis 2004;172:199–200.
Schreiner PJ, Wu KK, Malinow MR, Stinson VL, Szklo M, Nieto FJ, et al. Hyperhomocyst(e)inemia and homeostatic factors: the atherosclerosis risk in community studies. Ann Epidemiol 2002;12:228–36.
Abu-Mahfuz MZ, Prasad VM, Santogade P, Cutler AF. H. pylori recurrence after successful eradication: 5-year follow-up in the United States. Am J Gastroenterol 1997;92: 2025–8.
Roe DA. Drug and nutrient interactions. In: Bodwell CE, Erdman Jr JW, editors. Nutrient interactions Ift Basic Symposium Series. New York: Marcel Dekker; 1988. p. 365–77.
Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001;103: 1813–8.
Aronson D, Bartha P, Zinder O, Kerner A, Markiewicz W, Avizohar O, et al. Obesity is the major determinant of elevated C-reactive protein in subjects with the metabolic syndrome. Int J Obesity 2004;28:674–9.
Danesh J, Peto R. Risk factors for coronary heart disease and infection with Helicobacter pylori: meta-analysis of 18 studies. BMJ 1998;316:1130–2.
Wolf SC, Brehm BR, Mayer O, Ju¨rgens S, Schultze G. Risler T Infectious risk for atherosclerotic vascular disease in hemodialysis patients – Chlamydia pneumoniae but not Helicobacter pylori or cytomegalovirus is associated with increased C-reactive protein. Ren Fail 2004;26:279–87.
Kanbay M, Kasapoglu B, Turgut F, Uz E, Bavbek N, Akcay A. Helicobacter pylori: a major risk factor for endothelial dysfunction. Med Hypotheses 2007;69:227–8.
Lip GH, Wise R, Beevers G. Association of Helicobacter pylori with coronary heart disease. BMJ 1996;312:250–1.
Wald NJ, Law MR, Morris JK, Bagnall AM. Helicobacter pylori and mortality from ischaemic heart disease: negative result from a large, prospective study. BMJ 1997;315: 1199–201.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
This is an open access article distributed under the CC BY-NC license. https://doi.org/creativecommons.org/licenses/by/4.0/
About this article
Cite this article
Siddiqui, N.R., Garvey, W.T. & Khaled, M.A. H. pylori-induced higher C-reactive protein in obese African Americans. Artery Res 3, 39–42 (2009). https://doi.org/10.1016/j.artres.2009.01.004
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1016/j.artres.2009.01.004